Logo image of XLRN

Acceleron Pharma (XLRN) Stock Fundamental Analysis

NASDAQ:XLRN - Nasdaq -

178.75  -0.93 (-0.52%)

After market: 179.92 +1.17 (+0.65%)

Fundamental Rating

3

Taking everything into account, XLRN scores 3 out of 10 in our fundamental rating. XLRN was compared to 571 industry peers in the Biotechnology industry. The financial health of XLRN is average, but there are quite some concerns on its profitability. While showing a medium growth rate, XLRN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

XLRN had negative earnings in the past year.
XLRN Yearly Net Income VS EBIT VS OCF VS FCFXLRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 -50M -100M -150M

1.2 Ratios

Industry RankSector Rank
ROA -32.35%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XLRN Yearly ROA, ROE, ROICXLRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 -10 -20 -30 -40 -50

1.3 Margins

XLRN does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) -226%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XLRN Yearly Profit, Operating, Gross MarginsXLRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 -200 -400 -600 -800

More info and screens

6

2. Health

2.1 Basic Checks

XLRN has more shares outstanding than it did 1 year ago.
XLRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
XLRN Yearly Shares OutstandingXLRN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 20M 40M 60M
XLRN Yearly Total Debt VS Total AssetsXLRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 91.90 indicates that XLRN is not in any danger for bankruptcy at the moment.
There is no outstanding debt for XLRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 91.9
ROIC/WACCN/A
WACCN/A
XLRN Yearly LT Debt VS Equity VS FCFXLRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 0 200M 400M 600M 800M

2.3 Liquidity

XLRN has a Current Ratio of 12.14. This indicates that XLRN is financially healthy and has no problem in meeting its short term obligations.
XLRN has a Quick Ratio of 12.14. This indicates that XLRN is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 12.14
Quick Ratio 12.14
XLRN Yearly Current Assets VS Current LiabilitesXLRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 200M 400M 600M 800M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for XLRN have decreased strongly by -76.15% in the last year.
Looking at the last year, XLRN shows a small growth in Revenue. The Revenue has grown by 6.40% in the last year.
Measured over the past years, XLRN shows a very strong growth in Revenue. The Revenue has been growing by 38.58% on average per year.
EPS 1Y (TTM)-76.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75.76%
Revenue 1Y (TTM)6.4%
Revenue growth 3Y90.04%
Revenue growth 5Y38.58%
Sales Q2Q%51.59%

3.2 Future

XLRN is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -3.07% yearly.
The Revenue is expected to grow by 45.39% on average over the next years. This is a very strong growth
EPS Next Y-41.56%
EPS Next 2Y-8.05%
EPS Next 3Y8.29%
EPS Next 5Y-3.07%
Revenue Next Year41.05%
Revenue Next 2Y47.46%
Revenue Next 3Y45.08%
Revenue Next 5Y45.39%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
XLRN Yearly Revenue VS EstimatesXLRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
XLRN Yearly EPS VS EstimatesXLRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XLRN. In the last year negative earnings were reported.
Also next year XLRN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XLRN Price Earnings VS Forward Price EarningsXLRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -41
XLRN Per share dataXLRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.05%
EPS Next 3Y8.29%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XLRN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Acceleron Pharma

NASDAQ:XLRN (11/19/2021, 8:33:57 PM)

After market: 179.92 +1.17 (+0.65%)

178.75

-0.93 (-0.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)02-28 2022-02-28/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners17.97%
Ins Owner Change0%
Market Cap10.89B
Analysts72.94
Price Target182.68 (2.2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 96.59
P/FCF N/A
P/OCF N/A
P/B 15.17
P/tB N/A
EV/EBITDA -41
EPS(TTM)-4.21
EYN/A
EPS(NY)-3.39
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.85
BVpS11.79
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.35%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) -226%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.14
Quick Ratio 12.14
Altman-Z 91.9
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-76.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75.76%
EPS Next Y-41.56%
EPS Next 2Y-8.05%
EPS Next 3Y8.29%
EPS Next 5Y-3.07%
Revenue 1Y (TTM)6.4%
Revenue growth 3Y90.04%
Revenue growth 5Y38.58%
Sales Q2Q%51.59%
Revenue Next Year41.05%
Revenue Next 2Y47.46%
Revenue Next 3Y45.08%
Revenue Next 5Y45.39%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A